The variant was first identified in South Africa in November 2024 and has since spread across multiple regions, including Europe, North America, Asia, Africa, and Oceania. Its rapid geographical expansion has raised concerns among scientists.

According to health experts, BA.3.2 carries approximately 70 to 75 mutations in its spike protein—significantly higher than many previous strains. These mutations may allow the variant to partially evade immunity developed through vaccination or prior infection, making it a subject of close observation.

In the United States, the variant was first detected in June 2025 in a traveler arriving from Netherlands. Since then, it has been identified through airport screenings, clinical testing, and wastewater surveillance across several states. However, it currently represents only a small proportion of total COVID-19 cases.

Also Read: Suthra Punjab initiative: Govt plans dung tax to promote cleanliness and renewable energy

So far, there is no evidence suggesting that the Cicada variant causes more severe illness than other circulating strains. Nonetheless, laboratory findings indicating potential antibody evasion underscore the need for continued monitoring.

Health officials emphasize vigilance over alarm, noting that while BA.3.2 has not triggered a major surge, its mutation profile makes it one of the most closely watched variants globally.